Pierre Geneves

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

Retrieved on: 
Friday, December 9, 2022
Pediatrics, Immunotherapy, BioNTech, Clinical trial, Marketing, Omicron, Emergency Use Authorization, Safety, Originality, Science, Cancer, Peer review, Regeneron Pharmaceuticals, Pierre Geneves, News, Vaccine, RNA transfection, Hoffmann-La Roche, Infection, Research, Risk, Form 6-K, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Publication, Medical device, Genentech, Pfizer, BNT162

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Retrieved on: 
Thursday, December 8, 2022
Pediatrics, Immunotherapy, BioNTech, Clinical trial, FDA, Marketing, Omicron, Safety, Originality, Science, Cancer, Peer review, Regeneron Pharmaceuticals, DO, Pierre Geneves, News, Vaccine, Vaccination, EUA, RNA transfection, Hoffmann-La Roche, Infection, BNT162, Research, Risk, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Publication, Form, Pharmaceutical industry, Medical device, EU, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Retrieved on: 
Thursday, December 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, COVID-19, Clinical Trials, Pfizer–BioNTech COVID-19 vaccine, Publication, Vaccination, State, BioNTech, JD, Immunotherapy, Human services, Omicron, Infection, Science, Cancer, American Animal Hospital Association, Research, United States Department of Health and Human Services, Pediatrics, FDA, Vaccine, Peer review, Regeneron Pharmaceuticals, Form, News, Health, COVID-19, Pierre Geneves, Clinical trial, RNA transfection, Safety, Originality, Hospital, EUA, American Academy of Pediatrics, Hoffmann-La Roche, BNT162, Marketing, U.S. Department of Defense Strategy for Operating in Cyberspace, Risk, Pharmaceutical industry, Medical device, Pfizer, Genentech, EU

For more than 170 years, we have worked to make a difference for all who rely on us.

Key Points: 
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.pfizer.com .
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Retrieved on: 
Friday, November 18, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, BNT162, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, Ageing, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, Medical device, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

Retrieved on: 
Wednesday, November 16, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Retrieved on: 
Friday, November 4, 2022
BNT162, Company, Private Securities Litigation Reform Act, Science, Research, Awareness, Peer review, Ageing, RNA transfection, EMA, Cancer, Publication, Safety, BioNTech, Pediatrics, COVID-19, Marketing, YouTube, Omicron, Pierre Geneves, U.S. Securities and Exchange Commission, Originality, Regeneron Pharmaceuticals, Clinical trial, Vaccine, Risk, Infection, Hoffmann-La Roche, Form, Pfizer–BioNTech COVID-19 vaccine, SEC, Immunotherapy, News, Program, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Pharmaceutical, Health, BNT162, Company, Private Securities Litigation Reform Act, Science, Research, Awareness, Peer review, Ageing, RNA transfection, EMA, Cancer, Publication, Safety, BioNTech, Pediatrics, COVID-19, Marketing, YouTube, Omicron, Pierre Geneves, U.S. Securities and Exchange Commission, Originality, Regeneron Pharmaceuticals, Clinical trial, Vaccine, Risk, Infection, Hoffmann-La Roche, Form, Pfizer–BioNTech COVID-19 vaccine, SEC, Immunotherapy, News, Program, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Science, YouTube, Vaccine, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Vaccination, Science, YouTube, Vaccine, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, EUA, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, DO, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Retrieved on: 
Wednesday, October 12, 2022
LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Science, YouTube, EMA, Vaccine, Person, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, EUA, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us onand follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.